HER2-Positive Breast Cancer: After Trastuzumab, What's Next?

Program Description:

Despite clear evidence regarding the importance of a tumor’s molecular signature in treatment algorithms, too few clinicians routinely obtain such information. This webcast educates clinicians regarding the biochemical pathways that lead to trastuzumab resistance in HER2-positive tumors and current options to overcome such resistance or other options to increase progression-free survival.

INTENDED AUDIENCE:

Community oncologists, surgical oncologists, radiation oncologists, pathologists, oncology nurses, and other health care professionals involved in the care and treatment of women with breast cancer.

Activity Objectives:

At the end of this online enduring material, participants should be able to:

• Identify molecular pathways that contribute to endocrine and trastuzumab resistance and discuss their implications for treatment.


• Discuss the outcomes of the most recent clinical trials related to the management of women with treatment-resistant breast cancer, including those with triple-negative breast cancer.

Faculty:

Beverly Moy, MD, MPH
Clinical Director
The Breast Oncology Program
The MGH Cancer Center
Massachusetts General Hospital
Assistant Professor in Medicine
Harvard Medical School
MA

Disclosures:

It is the policy of The Society for Translational Oncology (STO) that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity. The Society for Translational Oncology (STO) has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.

Faculty
In accord with the disclosure policy of The Society for Translational Oncology (STO) as well as guidelines of the Accreditation Council for Continuing Medical Education (ACCME), planners, speakers and anyone who may have an influence on the content of the activity have been asked to disclose any relationship they or their spouse/partner have to companies producing pharmaceuticals, medical equipment, devices, etc. that may be germane to the content of their presentation. Such disclosure is not intended to suggest or condone bias, but provides participants with information that might be of potential importance to their evaluation of a given presentation.

The following planner of this activity has indicated that she and/or her spouse/partner do have a relevant financial relationship to disclose:
Beverly Moy, MD
Consulting: GlaxoSmithKline, Pfizer

The following speaker of this activity has indicated that she and/or her spouse/partner do have a relevant financial relationship to disclose:
Beverly Moy, MD
Consulting: GlaxoSmithKline, Pfizer

Accredited Provider:

Jointly sponsored by the Society for Translational Oncology and Massachusetts General Hospital.

Commercial Supporter:

Supported through an educational grant from Genentech, Novartis, and Genomic Health

Instructions:

Method of Participation:
To receive continuing education credit, participants should review all program materials in their entirety, complete and submit the online post-test and evaluation, and score at least 70% on the post-test. A statement of credit will be available for printing upon successful completion.

If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

SYSTEM REQUIREMENTS:

WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.

MACINTOSH^® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20 MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands of Colors”; Macromedia Flash Player 6 or higher.